Literature DB >> 30579705

Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.

Hemraj B Dodiya1, Christopher B Forsyth2, Robin M Voigt2, Phillip A Engen2, Jinal Patel2, Maliha Shaikh2, Stefan J Green3, Ankur Naqib3, Avik Roy4, Jeffrey H Kordower4, Kalipada Pahan4, Kathleen M Shannon5, Ali Keshavarzian6.   

Abstract

Recent evidence provides support for involvement of the microbiota-gut-brain axis in Parkinson's disease (PD) pathogenesis. We propose that a pro-inflammatory intestinal milieu, due to intestinal hyper-permeability and/or microbial dysbiosis, initiates or exacerbates PD pathogenesis. One factor that can cause intestinal hyper-permeability and dysbiosis is chronic stress which has been shown to accelerate neuronal degeneration and motor deficits in Parkinsonism rodent models. We hypothesized that stress-induced intestinal barrier dysfunction and microbial dysbiosis lead to a pro-inflammatory milieu that exacerbates the PD phenotype in the low-dose oral rotenone PD mice model. To test this hypothesis, mice received unpredictable restraint stress (RS) for 12 weeks, and during the last six weeks mice also received a daily administration of low-dose rotenone (10 mg/kg/day) orally. The initial six weeks of RS caused significantly higher urinary cortisol, intestinal hyperpermeability, and decreased abundance of putative "anti-inflammatory" bacteria (Lactobacillus) compared to non-stressed mice. Rotenone alone (i.e., without RS) disrupted the colonic expression of the tight junction protein ZO-1, increased oxidative stress (N-tyrosine), increased myenteric plexus enteric glial cell GFAP expression and increased α-synuclein (α-syn) protein levels in the colon compared to controls. Restraint stress exacerbated these rotenone-induced changes. Specifically, RS potentiated rotenone-induced effects in the colon including: 1) intestinal hyper-permeability, 2) disruption of tight junction proteins (ZO-1, Occludin, Claudin1), 3) oxidative stress (N-tyrosine), 4) inflammation in glial cells (GFAP + enteric glia cells), 5) α-syn, 6) increased relative abundance of fecal Akkermansia (mucin-degrading Gram-negative bacteria), and 7) endotoxemia. In addition, RS promoted a number of rotenone-induced effects in the brain including: 1) reduced number of resting microglia and a higher number of dystrophic/phagocytic microglia as well as (FJ-C+) dying cells in the substantia nigra (SN), 2) increased lipopolysaccharide (LPS) reactivity in the SN, and 3) reduced dopamine (DA) and DA metabolites (DOPAC, HVA) in the striatum compared to control mice. Our findings support a model in which chronic stress-induced, gut-derived, pro-inflammatory milieu exacerbates the PD phenotype via a dysfunctional microbiota-gut-brain axis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intestinal barrier; Intestinal hyper-permeability; Microbiome dysbiosis; Microbiota-gut-brain axis; Neurodegenerative disease; Parkinson's disease; Peripheral inflammation; Rodent behavior

Mesh:

Substances:

Year:  2018        PMID: 30579705     DOI: 10.1016/j.nbd.2018.12.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  51 in total

Review 1.  The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.

Authors:  Ai Huey Tan; Shen Yang Lim; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2022-06-24       Impact factor: 44.711

2.  Multi-omic Analysis of the Gut Microbiome in Rats with Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy.

Authors:  Maria Eduarda T Oliveira; Gustavo V B Paulino; Erivaldo D Dos Santos Júnior; Francisca A da Silva Oliveira; Vânia M M Melo; Jeferson S Ursulino; Thiago M de Aquino; Ashok K Shetty; Melissa Fontes Landell; Daniel Leite Góes Gitaí
Journal:  Mol Neurobiol       Date:  2022-08-13       Impact factor: 5.682

Review 3.  Inflammatory Animal Models of Parkinson's Disease.

Authors:  Juan García-Revilla; Antonio J Herrera; Rocío M de Pablos; José Luis Venero
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 4.  The Microbiome as a Modifier of Neurodegenerative Disease Risk.

Authors:  P Fang; S A Kazmi; K G Jameson; E Y Hsiao
Journal:  Cell Host Microbe       Date:  2020-08-12       Impact factor: 21.023

Review 5.  Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.

Authors:  Vinod Metta; Valentina Leta; Kandadai Rukmini Mrudula; L K Prashanth; Vinay Goyal; Rupam Borgohain; Guy Chung-Faye; K Ray Chaudhuri
Journal:  J Neurol       Date:  2021-04-21       Impact factor: 4.849

Review 6.  The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.

Authors:  Nitu Dogra; Ruchi Jakhmola Mani; Deepshikha Pande Katare
Journal:  Cell Mol Neurobiol       Date:  2021-03-02       Impact factor: 5.046

7.  Neuroprotective effects of curcumin on the cerebellum in a rotenone-induced Parkinson's Disease Model.

Authors:  Heba Fikry; Lobna A Saleh; Sara Abdel Gawad
Journal:  CNS Neurosci Ther       Date:  2022-01-23       Impact factor: 5.243

8.  Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease.

Authors:  Ruwani S Wijeyekoon; Deborah Kronenberg-Versteeg; Kirsten M Scott; Shaista Hayat; Wei-Li Kuan; Jonathan R Evans; David P Breen; Gemma Cummins; Joanne L Jones; Menna R Clatworthy; R Andres Floto; Roger A Barker; Caroline H Williams-Gray
Journal:  Brain Behav Immun       Date:  2020-01-30       Impact factor: 19.227

Review 9.  Neurodegenerative disorders and gut-brain interactions.

Authors:  Alpana Singh; Ted M Dawson; Subhash Kulkarni
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

Review 10.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.